Assessment of Pharmacovigilance Across University Hospitals in Morocco

Hind Hamzaoui, Anna Shaum, Imad Cherkaoui, Latifa Ait Moussa, Houda Sefiani, Ismail Talibi, Ghita Benabdallah, Omar Salman, Seth Ferrey and Rachida Soulaymani Bencheikh ()
Additional contact information
Hind Hamzaoui: Ministry of Health
Anna Shaum: US Centers for Disease Control and Prevention
Imad Cherkaoui: Private Consultant
Latifa Ait Moussa: Ministry of Health
Houda Sefiani: Ministry of Health
Ismail Talibi: Ministry of Health
Ghita Benabdallah: Ministry of Health
Omar Salman: US Centers for Disease Control and Prevention
Seth Ferrey: US Centers for Disease Control and Prevention
Rachida Soulaymani Bencheikh: Ministry of Health

Drug Safety, 2025, vol. 48, issue 5, No 6, 527-539

Abstract: Abstract Introduction Despite the increased scrutiny on vaccine safety following the coronavirus disease 2019 (COVID-19) pandemic, Morocco’s Centre of Antipoison and Pharmacovigilance (CAPM) remained concerned that the pharmacovigilance system in Morocco was insufficiently implemented, including limited adverse event (AE) reporting, poor data use, and inconsistent training nationwide. Objectives We sought to assess the status of pharmacovigilance activities (PAs) prior to formally institutionalizing them across university hospital centers (UHCs), given their position as the main providers of healthcare in Morocco and key sources for reporting serious AEs. Methods We assessed seven UHCs (housing 30 hospitals) in 2023 using a structured questionnaire with pharmacovigilance focal points developed from the World Health Organization’s indicators of pharmacovigilance and the Global Benchmarking Tool. Data were grouped into 28 PAs and scored from 0 (not implemented) to 3 (fully implemented). We then calculated an implementation rate for each site on the basis of percent of PAs fully implemented (≥ 70%, well established; > 40% to

Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40264-025-01517-w Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:drugsa:v:48:y:2025:i:5:d:10.1007_s40264-025-01517-w

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/40264

DOI: 10.1007/s40264-025-01517-w

Access Statistics for this article

Drug Safety is currently edited by Nitin Joshi

More articles in Drug Safety from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().